David Lee, MD, PhD

As a physician, researcher, and executive leader, Dr. David’s career reflects a deep commitment to transforming patients’ lives through innovative science and strategic business approaches. He joined Johnson & Johnson in 2018 to lead an organization focused on discovering, developing, and delivering treatments for immune-mediated diseases. Under his leadership, the team has launched some of J&J’s most impactful medicines, including STELARA®, TREMFYA®, and IMAAVY™. Previously, David served as Global Head of Immunology, Inflammation, and Infectious Disease Discovery at Roche in Basel, Switzerland, and Global Head of Autoimmunity, Dermatology, and Transplant Translational Medicine at Novartis Institutes for BioMedical Research. Before entering industry, David was a practicing rheumatologist and ran an NIH-funded translational research lab at Brigham and Women’s Hospital/Harvard Medical School. He authored more than 80 peer-reviewed publications and book chapters and delivered over 100 lectures. While at Harvard, he also founded or co-founded three biotech companies backed by venture capital. David earned both his MD and PhD in Microbiology/Immunology from Duke University School of Medicine. His passion for developing new medicines is rooted in his firsthand experience treating patients and striving to meet their unmet needs.